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1064-146 Incidence of Biopsy-Proven Cardiac Transplant 
Rejection Through the 90's Decade 
Maria L. Espejo, Sumeet Subherwal, ~gn A. Kobashieawa, University of California, Los 
Angeles Medical Center, Los Angeles, California. 
The endomyocardial biopsy (Embx) has been the standard to detect rejection in cardiac 
transplant patients and used as a primary endpoint in immunosuppression trials, The 
incidence of rejections in the first year after transplant has been reported as decreasing 
but this trend has not been well established clue to differences in Embx interpretation 
(reading) and protocols among various cardiac transplant programs. Dudng the past 
decade in our single center experience, Embx protocol and interpretation has been con- 
sistent (one predominant reviewer). All Embxs in the first year after transplant were 
assigned International Society of Heart/Lung Transplant (ISHLT) grades and reviewed 
from 1990 through 2000 to assess the incidence of biopsy-proven rejection. 6892 Embxs 
were performed in 536 cardiac transplant patients in the first year after transplant. 
Cyclospodne based immunosuppression (no cytolytic induction) was used in greater 
than 95% at time of Embx with the remainder under tecrolimus. Since 1998, mycopheno- 
late mofetil has replaced azathioprine as part of a triple drug regimen. From 1990 to 
2000, the number of biopsy*proven rejections (defines as ISHLT grade > 3A) has 
decreased, Conclusion: Biopsy-proven rejection has decreased through the 90's decade 
in cardiac transplant patients concomitant with improved immunosuppressive therapies. 
This will impact future immunosuppression tdals that use biopsy-proven rejection as an 
endpoint as more study patients will be needed to show differences. 
Year '90-'91 '92-'93 '94-'95 '96-'97 '98-'99 2000 
# Patients 96 65 91 124 99 61 
# Embxs 1233 851 1204 1574 1221 809 
% Embx _> 3A 7.9% 5.1% 4.0% 3.3% 2.5% 0.2% 
1064-147 Disposit ion of Patients Referred for Cardiac 
Transplantation to a Tertiary Specialized Heart Failure 
Center in Contemporary Clinical Practice 
Renee Bennett, Niall G, Mahon, Katherine Hoercher, Nicholas G. Smedira, James B. 
Young, Patrick M. McCarthy, Randall C. Starling, Cleveland Clinic Foundation, 
Cleveland, Ohio. 
Background: The growing epidemic of congestive heart failure in the setting of limited 
donor-organ availability has mandated continued development and increased utilization 
of medical and surgical alternatives to cardiac transplantation, 
Aim: To assess current disposition and outcomes of patients recently referred for trans- 
plant evaluation to a single high throughput ertiary referral center, 
Methods: Consecutive transplant referrals (1995 through 2000) meeting the following cri- 
teria were analyzed: (i) assessed initially in an outpatient setting by a heart failure cardi- 
ologist (ii) formally presented to a transplant selection committee for final disposition. 
Results: Of 1147 consecutive referrals meeting above criteria (mean age 57.2 (±12.1), 
73% male), 562 (49%) were recommended medical treatment (mean age 55.7 (±16.5), 
72% male) and 178 (16%) non-transplant surgery, pdncipally coronary artery bypass 
grafting, mitrat valve repair, infarct exclusion, partial eft ventdculectomy, or combinations 
thereof (mean age 58,7 (±9.5), 75% male). 405 (35%) were listed for cardiac transplanta- 
tion (mean age 58.1 (=7.2), 74% male), Of these, 72 (18% of listed) died waiting (34 on 
LVAD support), 46 were de-listed (25 for improved clinical status) and 209 (18% of 
referred group) have been transplanted. 1-year survival (Kaplan-Meier) was 87,1% in the 
transplanted group and 82.4% in the non-transplant surgery group (p=ns). 
Conclusion: In current clinical practice <1/5 of transplant referrals are ultimately trans- 
planted, reflecting both a limited donor supply and a growing armamentadum of alterna- 
tives. Medium term survival in patients suitable for alternative surgical strategies 
approaches that of cardiac transplantation. 
1064-148 Tacrolimus (FK506) Versus Cyclosporine 
Nephrotoxiclty in Heart Transplant Recipients: A Four- 
Year Follow-Up 
Hans-Ulrich Stemofle, Monika Hien, Bruno Meiser, Robert Frost, Rainer Schrepf, Bruno 
Reichart, Karl Theisen, Med. Klinik - Innenstadt, DepL of Cardiology, Munich, Germany, 
Heart Surgery, Klinikum Grosshadem, Munich, Germany 
Background: The macrolide lactone tacrolimus (FK508) is a relatively new immunosup- 
pressive drug in heart transplantation (HTx) which has demonstrated to be more potent 
and effective than cyclosporine A (CyA). Although clinical studies revealed comparable 
short-term nephrotoxic effects, there is limited knowledge about the effects of long-term 
FK506 therapy on glomerular and tubular functions after HTx. Methods: We compared 
60 heart transplant recipients (pts.; 8f, 52m, mean age: 56±11yrs.) with a maintenance 
immunosuppression of FK506 (target serum levels of 10-15 ng/mL; RIA) with 34 pts. (3f, 
31m, mean age 53±9 yrs.) using a CyA maintenance immunosuppression (target serum 
levels of 100-200 ng/mL; RIA) retrospectively over 48 months. Renal function was evalu- 
ated frequently after HTx (early, 6, 12, 24, 36, 48 months) by measurements of serum/ 
urinary calcium, phosphate, creatinine (Cr) and serum intact parathyroid hormone. Crea- 
tinine clearance (CrCI) was calculated using 24-hour udne collections. Glomerular and 
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tubular functions were assessed by renal excretion of protein, albumin, al-micro- and a2- 
macroglobulin. Results: Using FK506, CRCI decreased continuously within 48 months 
from 74±25 ml/min to 53±19 ml/min (p<0.05). This was paralleled by an increase of Cr 
from 1.4±0.4 mg/dl to 2.1±1.0 mg/dl (p<0.01). Pts. with CyA showed a comparable (n.s.) 
decrease in CrCI (72±32 ml/min to 53±21 ml/min) as well as increase in Cr (1.5±0.4 rag/ 
dl to 1.9±0.5 mg/dl; p<O.05). A significant increase in albumin excretion occurred in 42% 
of the FK506-pts., which was within the microalbuminuria r nge in 25%. al-microglobulin 
was slightly increased in 42% and severely increased in 17% of pts. due to tubu~ointersti- 
tial nephropathy. One patients developed end-stage renal disease. In comparison, 41% 
of CyA-pts. showed an increased albumin excretion (86% microalbuminuria). 59% of 
CyA-pts. revealed a tubulointerstitial damage (severe in 41%). Conclusions: A Tecroli- 
mus based immunosuppression impairs progressively the long-term renal function com- 
parable to CyA, GIomerular and/or tubolointerstitial renal damage is already seen in 
more than haft of the patients with both immunosuppressive r gimens. 
1064-149 Peripheral Vascular Endothelial Function Predicte 
Exercise Capacity in Cardiac Transplant Recipients 
Avan R. Patel. Jeffrey T. Kuvin, David DeNofrio, Debra Kinan, Kathfeen A. Sliney, Kalyani 
P. Erenki, Natesa G. Pandian, James E. Udelson, Marvin A. Konstam. Richard H. Karas, 
New England Medical Center, Boston, Massachusetts. 
BACKGROUND: Exercise capacity is impaired in patients with heart failure, but does not 
correlate well with ejection fraction or resting hemodynamics. Peripheral factors, such as 
vascular endothelial function (which is abnormal in patients with heart failure), may there- 
fore contdbute to this functional limitation. Since exercise capacity often remains 
impaired after cardiac transplant (Tx), we sought to determine if peripheral endothelium- 
dependent vasodilation predicts exercise time in Tx recipients. METHODS: Exercise 
myocardial perfusion testing (Bruce Protocol) was performed in stable Tx patients. 
Patients were excluded if they had evidence of iechemia, failed to reach anaerobic 
threshold, or stopped for symptoms other than dyspnea or fatigue. Endothelium-depen- 
dent vasodilation was assessed by using high resolution brachiat artery ultrasound to 
determine flow-mediated vasodilation (FMD). FMD was expressed as the percent 
change in brachial artery diameter during reactive hyperemia relative to baseline. 
RESULTS: 17 patients (mean age 58=10 years) were studied; 13 of these patients also 
underwent metabolic testing during exercise. The mean time since Tx was 4±3 years 
(range 1-10), and mean left ventricular ejection fraction was 62±7% (range 52-77%). 
Mean exercise time was 455±109 seconds and mean FMD was 9±3%. There was a lin- 
ear correlation between FMD and exercise time (r=0.569, p=0.02). Multiple linear regres- 
sion analysis demonstrated that this association was independent of age. Patients with 
FMD>9% had a higher mean exercise time than those with FMD<=9% (508±110 vs 
396±76 seconds, p<0.05). In patients who underwent concurrent metabolic testing dur- 
ing exercise, FMD was strongly correlated with the duration of exercise after reaching 
'anaerobic threshold (r=0.737, p<0.005), but not with time to anaerobic threshold. CON- 
CLUSION: Peripheral endothelium-dependent vasodilation correlates with exercise 
capacity in Tx recipients. Further studies are needed to determine whether interventions 
targeted at restoring endothelial function may improve functional capacity in this popula- 
tion. 
1064-150 Survivors More Than 10 Years After Heart 
Transplantation in the Cyclosporine Era 
Nobuvuki Shiba, Michael C. Chan, Bernard W. Kwok, Robert C. Robbins, Hannah A. 
Valantine, Sharon A. Hunt, Stanford University, Stanford, California. 
Background: Increasing numbers of heart transplant(HTx) recipients are surviving truly 
long-term and requiring complex levels of medical care. 
Methods: As of May 1, 2001, 1074 patients have undergone HTx at our center since 
1968 and 200 of these survived beyond 10 years. We reviewed the status of 143 adults 
who survived more than 10 years and whose initial regimen included cyclosporine(CsA). 
Reeulta: The age at HTx for the 10-year survivors was 41.4±11.6 years (mean±SD); 
77% were male. The patients' underlying disease was: idiopathic ardiomyopathy 42.0%, 
coronary artery disease(CAD) 34.3%, viral cardiomyopathy 9.1%. Mean follow-up time 
was 151±22 months. The patients' functional status in the 10th year was good: NYHA-I 
90%, NYHA-II 5%. Body mass index increased significantly compared to pre- 
HTx(23.7±4.1 vs. 27.9±6.7, p<0.001). Their immunosuppressive regimens in the 10th 
year were: CsNazathioprine(AZA)/prednisone(P) 49.7%, CsNP 12.6%, CsNAZA 
12.6%, CsNmycophenolate mofetil /P 7.7%. P was still used overall in 
69.2%(0.11±0.07mg/kg.day). Anti-hypertensive drugs were required by 81% at the 10th 
year and they included: calcium-blocker 49%, ACE inhibitor 30%, diuretics 21%, beta- 
blocker 17%. Twenty-one(14.7%) had diabetes and 11.2% required insulin. Statins were 
used in 39%. Renal dysfunction(Cr >3.0mg/dl) developed in 39.2% at mean of 59± 
47months after HTx and 10.5% underwent hemodialysis or peritoneal dialysis; 12 
patients (8.4%) underwent kidney transplantation at 101=45 months after HTx. Types of 
malignancy were: lymphoma in 7.7%(103±50 months), non-lymphoid malignancy 
32.2%(96±45 months): skin cancer 28.7%, solid organ cancer 7.0%. Thirty five 
patients(24.5%) had significant angiographic CAD(>50% stenosis in a main epicardial 
artery) at mean of 90±40 months after HTx and 15(10.5%) had angioplasty +/- stenting. 
Forty two of the patients(29.4%) have died and main causes of death were graft CAD 
(31.0%) and malignancy (30.9%). Two(1.4%) patients underwent re-HTx. 
Conclusions: Patients who survived beyond 10 years after HTx on a CsA-based regi- 
men mostly have excellent functional status. However, renal dysfunction, malignancy 
and graft CAD remain clinical threats to them. 
